BR9807262A - Composições farmacêuticas incorporando compostos de amina olefìnica substituìda com arila - Google Patents

Composições farmacêuticas incorporando compostos de amina olefìnica substituìda com arila

Info

Publication number
BR9807262A
BR9807262A BR9807262-5A BR9807262A BR9807262A BR 9807262 A BR9807262 A BR 9807262A BR 9807262 A BR9807262 A BR 9807262A BR 9807262 A BR9807262 A BR 9807262A
Authority
BR
Brazil
Prior art keywords
alkyl
amine
buten
methyl
hydrogen
Prior art date
Application number
BR9807262-5A
Other languages
English (en)
Inventor
William Scott Caldwell
Gary Maurice Dull
Grayland Page Dobson
Craig Harrison Miller
Merouane Bencherif
Patrick Michael Lippiello
Original Assignee
Reynolds Tobacco Co R
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/804,250 external-priority patent/US6531606B1/en
Priority claimed from US08/804,248 external-priority patent/US5861423A/en
Application filed by Reynolds Tobacco Co R filed Critical Reynolds Tobacco Co R
Publication of BR9807262A publication Critical patent/BR9807262A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Patente de Invenção:<B>"COMPOSIçõES FARMACEUTICAS INCORPORANDO COMPOSTOS DE AMINA OLEFìNICA SUBSTITUìDA COM ARILA"<D>. Pacientes suscetíveis ou sofrendo de distúrbios do sistema nervoso central (por exemplo, mal de Alzhemier, mal de Parkinson, síndrome de Tourette, distúrbio de défcit de atenção, ou esquizofrenia) são tratados por administração de uma quantidade eficaz de um composto de amina olefínica substituído com arila de Fórmula (I): onde X é C-R', C-OR', C-CH~ 2~-OR' onde R' é selecionado do grupo consistindo em H, C~ 1-5~ alquila, uma espécie contendo grupo aromático, e espécies contendo grupo aromático substituído com alquila, halo ou amino; E' é hidrogênio ou C~ 1-5~ alquila ou C~ 1-5~ alquila substituído com halo; E" é c~ 1-5~ alquila ou C~ 1-5~alquila substituído com halo; Z' e Z" são cada um individualmente selecionados do grupo consistindo em hidrogênio, C~ 1-5~alquila, anéis arila, e podem formar uma estrutura de anel (a), A, A'e A" são cada um individualmente selecionados do grupo consistindo em hidrogênio, C~ 1-7~ alquila,, e halo; m é 0 ou 1; p é 0 ou 1 com a condição de que quando m ou p é 0 então E" é hidrogênio; e a linha ondulada na estrutura representa uma forma cis(Z) ou trans(E) do composto. Compostos exemplares incluem (E)-N-metil-4-[3-(benzilóxi piridin) il]-3-buten-1-amina, (E)-N-metil-4-[3-(5-fenóxi piridin) il]-3-buten-1-amina, (E)-N-metil--4[3-(5-isopropóxi piridin) il]-3-buten-1-amina, (E)-N-metil-4-[3-(5-metóxi metil piridin) il]-3-buten-1-amina, e (E)-N-metil-4-[3-(5-fenil piridin) il]-3-buten-1-amina.
BR9807262-5A 1997-02-21 1998-02-19 Composições farmacêuticas incorporando compostos de amina olefìnica substituìda com arila BR9807262A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/804,250 US6531606B1 (en) 1997-02-21 1997-02-21 Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
US08/804,248 US5861423A (en) 1997-02-21 1997-02-21 Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
PCT/US1998/003091 WO1998037071A1 (en) 1997-02-21 1998-02-19 Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds

Publications (1)

Publication Number Publication Date
BR9807262A true BR9807262A (pt) 2000-05-23

Family

ID=27122682

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9807262-5A BR9807262A (pt) 1997-02-21 1998-02-19 Composições farmacêuticas incorporando compostos de amina olefìnica substituìda com arila

Country Status (12)

Country Link
EP (1) EP0973743B1 (pt)
JP (1) JP2001512486A (pt)
KR (1) KR100572189B1 (pt)
AT (1) ATE274496T1 (pt)
AU (1) AU749151B2 (pt)
BR (1) BR9807262A (pt)
CA (1) CA2281564A1 (pt)
DE (1) DE69825879T2 (pt)
DK (1) DK0973743T3 (pt)
ES (1) ES2226095T3 (pt)
PT (1) PT973743E (pt)
WO (1) WO1998037071A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6979695B2 (en) * 1996-04-23 2005-12-27 Targacept, Inc. Compounds capable of activating cholinergic receptors
US20020052497A1 (en) 2000-03-09 2002-05-02 Targacept, Inc. Compounds capable of activating cholinergic receptors
US20050131034A1 (en) 1998-06-16 2005-06-16 Caldwell William S. Compounds capable of activating cholinergic receptors
WO1999065876A1 (en) * 1998-06-16 1999-12-23 R.J. Reynolds Tobacco Company Aryl substituted olefinic amines and their use as cholinergic receptors agonists
US7790757B2 (en) 1998-06-16 2010-09-07 Targacept, Inc. Compounds capable of activating cholinergic receptors
US6232316B1 (en) 1998-06-16 2001-05-15 Targacept, Inc. Methods for treatment of CNS disorders
JP2003501416A (ja) * 1999-06-07 2003-01-14 ターガセプト，インコーポレイテッド 医薬組成物およびその使用法
US20140150787A1 (en) * 2012-12-04 2014-06-05 Civitas Therapeutics, Inc. Devices and methods for puncturing a capsule to release a powdered medicament therefrom

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9407447D0 (en) * 1994-04-14 1994-06-08 Glaxo Group Ltd Chemical compounds
ATE334120T1 (de) * 1995-01-06 2006-08-15 Targacept Inc Pharmazeutische zusammensetzungen zur vorbeugung und behandlung von störungen des zentralnervensystems
US5616707A (en) * 1995-01-06 1997-04-01 Crooks; Peter A. Compounds which are useful for prevention and treatment of central nervous system disorders
US5616716A (en) * 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds

Also Published As

Publication number Publication date
JP2001512486A (ja) 2001-08-21
ES2226095T3 (es) 2005-03-16
EP0973743A1 (en) 2000-01-26
ATE274496T1 (de) 2004-09-15
KR100572189B1 (ko) 2006-04-18
PT973743E (pt) 2004-11-30
DE69825879D1 (de) 2004-09-30
AU6280698A (en) 1998-09-09
DK0973743T3 (da) 2004-11-29
CA2281564A1 (en) 1998-08-27
WO1998037071A1 (en) 1998-08-27
KR20000075531A (ko) 2000-12-15
AU749151B2 (en) 2002-06-20
DE69825879T2 (de) 2005-09-01
EP0973743B1 (en) 2004-08-25

Similar Documents

Publication Publication Date Title
RS74904A (en) Substituted pyridinones as modulators of p38 map kinase
MXPA05009359A (es) Tetrahidroisoquinolinas 2,5- y 2,6 substituidas para uso como moduladores 5-ht6.
UA66825C2 (uk) Азаполіциклічні сполуки, конденсовані з арилом, фармацевтична композиція, спосіб лікування та спосіб зниження нікотинової залежності
HUP0302167A2 (hu) Metabotropikus glutamát receptor antagonista hatású kinolinszármazékok, a vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
BR9408450A (pt) Antagonistas da neuroquinina diazabiciclicos
MY140693A (en) [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
TR200003478T2 (tr) Antikanser maddeleri olarak faydalı izotiyazol türevleri
HUP0200469A2 (hu) Szulfamátszármazékok alkalmazása az impulzus kontrol zavarok kezelésére
MXPA04005456A (es) Derivados de acetileno que tienen actividad antagonistica de mglur5.
ES2160640T3 (es) Nuevos (r)-5-carbamoil-8-fluoro-3-amino disustituido en n,n-3,4-dihidro-2h-1-benzopiranos.
MXPA05007496A (es) Tienopirimidindionas y su uso en la modulacion de enfermedades autoinmunes.
CA2406080A1 (en) Antitumoral ecteinascidin derivatives
HUP0002843A2 (hu) Új béta-karbolin-származékok, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények
SE0201544D0 (sv) Novel compounds and thier use
MY120976A (en) 2-amino-6-(2-substituted-4-phenoxy)- substituted- pyridines
HUP0303254A2 (hu) Új pirimidinvegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
EA200601194A1 (ru) Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором
SE9902765D0 (sv) Novel compounds
AU4610896A (en) Pharmaceutical compositions for prevention and treatment of central nervous system disorders
BR9807262A (pt) Composições farmacêuticas incorporando compostos de amina olefìnica substituìda com arila
WO2005066166A3 (en) 3-quinuclidinyl amino-substituted biaryl derivatives
MXPA05004273A (es) Derivados de fenilalquil y piridilalquil piperazina.
SE9902551D0 (sv) Novel compounds
DE69808922D1 (de) Thiazolobenzoheterocyclen, ihre herstellung und diese enthaltende phatrmazeutische zubereitungen
WO2002024641A1 (fr) Composes indol tricycliques possedant une affinite pour le recepteur de serotonine

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL: C07D 213/65, A61P 25/16, A61P 25/18

Ipc: C07D 213/65 (2007.10), A61P 25/16 (2007.10), A61P

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE O MESMO NAO ATENDE AO REQUISITO DE NOVIDADE ( ART. 8O C/C ART. 11 DA LPI )

B12B Appeal against refusal [chapter 12.2 patent gazette]